Skip to main content
Open
Question
Forecasts
Track record
Unknowns
How it works
Sources
FAQ
Menu
← Evidence map
Article
Nature cancer
2023
Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants.
PubMed ↗
Publisher ↗
No numbers read from the abstract.
Not cited yet
Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants. | OpenQuestion